345
Participants
Start Date
August 25, 2015
Primary Completion Date
September 18, 2020
Study Completion Date
September 18, 2020
lurbinectedin (PM01183)
Institut Jules Bordet, Brussels
Centre Hospitalier Universitaire Vaudois, Lausanne
Istituto Oncologico della Svizzera Italiana (IOSI), Bellinzona
Charité Universitätsmedizin Berlin - Campus Benjamin Franklin - Comprehensive Cancer Center, Berlin
Charité - Universitätsmedizin Berlin, Berlin
Complejo Hospitalario Regional Reina Sofía, Córdoba
Complexo Hospitalario Universitario A Coruña, A Coruña
Complexo Hospitalario Universitario de Santiago, Santiago de Compostela
Hospital Universitario Virgen de las Nieves, Granada
Hopsital Universitario Donostia - Donostia Unibertsitate Ospitalea, San Sebastián
Istituto Clinico Humanitas, Rozzano
ASST Monza - Ospedale San Gerardo di Monza Struttura Complessa di Oncologia Medica, Monza
lstituto Europeo di Oncologia, Milan
Skane University Hospital, Lund
Hospital Ramón y Cajal, Madrid
Hospital Universitario Fundación Jiménez Díaz, Madrid
Hospital Universitario 12 de Octubre, Madrid
Hospital Universitario Madrid Sanchinarro, Madrid
Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda
Complejo Hospitalario de Especialidades Virgen de la Victoria, Málaga
Complejo Hospitalario De Navarra, Pamplona
Institut Claudius Regaud, Toulouse
Hospital Universitario Central de Asturias, Oviedo
Hospital Universitario Álvaro Cunqueiro, Vigo
Hospital Universitari i Polotècnic la Fe, Valencia
Hospital de Basurto, Bilbao
AUSL Romagna - Ospedale Santa Maria delle Croci, Ravenna
Hospital Universitario Miguel Servet, Zaragoza
Hôpital Cochin, Paris
The University of Texas MD Anderson Cancer Center, Houston
Institute for Drug Development, Cancer Therapy & Research Center at University of Texas Health Science Center, San Antonio
University of Colorado Cancer Center, Aurora
Sarcoma Oncology Research Center, LLC, Santa Monica
Institut Gustave Roussy, Villejuif
Massachussets General Hospital, Boston
Beth Israel Deaconess Medical Centre, Boston
Dana Farber Cancer Institute, Boston
Istituto Ortopedico Rizzoli, Bologna
Hospital Universitari Vall D' Hebron, Barcelona
UCL Cancer Institute, London
Lead Sponsor
PharmaMar
INDUSTRY